During the past trading week (July 29 to August 2), a new financial results release signaled a potential turn of the page for Canadian cannabis producer Aphria (NYSE:APHA,TSX:APHA).

More insights into the CannTrust Holdings (NYSE:CTST,TSX:TRST) situation made headlines, while the decriminalization of marijuana in New York also caught attention.

Here’s a closer look at some of the biggest news during last week’s trading period.


US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

Shares of Aphria jump following positive quarter

Aphria shocked the market with its fiscal Q4 and year-end results on Thursday (August 1), reporting positive net income of C$15.8 million during the latest quarter.

For the 12 month period ended on May 31, 2019, Aphria reported net income of C$29.5 million. Interim Aphria CEO Irwin Simon said the results represent a new day for the company. “Over the last six months, our organization identified immediate priorities to help generate substantial progress near-term and long-term,” he said in a press release.

“We built upon existing business fundamentals and capabilities, streamlined processes, strengthened governance, and focused on building brand awareness,” Simon added.

The company credited the results to C$99.2 million in distribution revenue from CC Pharma, its German pharmaceutical distributor subsidiary.

Aphria is now projecting revenue of between C$650 million and C$700 million in its 2020 fiscal year.

Shares of the Canadian producer surged in New York and Toronto following the financial results, opening at US$6.74 and C$8.94, respectively. As of 1:04 p.m. EDT on Friday (August 2), shares of the producer were up over 30 percent on both exchanges.

CannTrust faces OSC investigation

CannTrust informed shareholders that — in addition to a projected delay in its upcoming financial report — the company is now being investigated by the Ontario Securities Commission (OSC).

“Today, staff of the OSC advised the Special Committee’s legal counsel that an investigation has been opened into matters and parties related to CannTrust and the investigation has been assigned to the Joint Serious Offences Team of the Enforcement Branch of the OSC,” the firm indicated on Friday.

A recent Globe and Mail report also shows CannTrust executives made millions from insider selling. This news came right after an internal email showed company communication on the illicit operations.

Co-founder and former board chair Eric Paul — who also previously served as CEO of the company alongside Director Mark Litwin — sold approximately C$1 million worth of CannTrust shares on November 16, 2018. An additional C$5 million in shares were sold through Cannamed Financial, a holding company.

New York decriminalizes marijuana

Also last week, New York Governor Andrew Cuomo (D) signed a bill officially decriminalizing marijuana use and possession in the state. However, the state failed to introduce a full legalization program after reported disputes on where to allocate tax revenue from a full cannabis program.

“It’s not legalization,” Cuomo said, according to NBC New York. “But it is decriminalization and it’s a major, major accomplishment.”

On Monday (July 29), representatives Nydia M. Velázquez (D-NY) and Steve Stivers (R-OH) introduced the Clarifying Law Around Insurance Marijuana (CLAIM) Act into Congress. This proposed bill would allow insurers to offer services to players in the marijuana industry, despite the federal illegality of the drug.

“Without this legislation, insurers will understandably be reticent to insure businesses operating in the cannabis sector,” Velázquez said in a statement. “This means a legal cannabis distributor whose product is ruined from a flood or fire could lose all their capital and their livelihood.

Market updates

Colorado-based Dixie Brands (CSE:DIXI.U,OTCQX:DXBRF) told the Investing News Network (INN) that its upcoming FUSE line of beverage products will bring the launch of brand new water-soluble drink additives containing THC.

“In this case we’ll have flavored THC as well as non-flavored THC drink additives. If somebody has tea or coffee or … orange juice and they want to put some THC in it, they’ll be able to do that,” explained Chuck Smith, CEO of Dixie.

Smith expressed an optimistic outlook for cannabis-infused drinks moving forward and indicated that his company’s entire line of products is planned to be available in Canada through a partnership with Auxly Cannabis Group (TSXV:XLY,OTCQX:CBWTF)

According to a new co-authored report from PwC Canada and CB Insights, cannabis investment from private money is seeing a downturn in 2019. So far in the year, US$42 million has been raised through 18 total deals. In 2018, US$224 million was raised across 51 deals.

“After unprecedented highs in 2018, this year has seen less funding and fewer deals for Canadian companies,” Anand Sanwal, co-founder and CEO of CB Insights, said in a press release.

The Florida market keeps expanding, with multi-state operator (MSO) Harvest Health & Recreation (CSE:HARV,OTCQX:HRVSF) confirming the opening of its sixth dispensary on Thursday.

Last month, the Florida Office of Medical Marijuana Use indicated that there were 144 active dispensaries in the state as of July 26. While Florida remains a medical-only market, the CEO of a fellow MSO ⁠— Kim Rivers with Trulieve Cannabis (CSE:TRUL,OTC Pink:TCNNF) ⁠— previously told investors she expects a vote on adult use by the 2024 ballot.

On Thursday (August 1), Aleafia Health (TSX:ALEF,OTCQX:ALEAF) reported its biggest recreational cannabis sale through its recently acquired subsidiary Emblem.

The C$1 million sale raised Aleafia Health’s monthly gross revenues average to a higher mark than the recorded revenue generated throughout 2018.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.


US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less